Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;130(8):1579-1588.
doi: 10.1002/jso.27856. Epub 2024 Sep 30.

Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma

Asmita Chopra  1 , Anthony Gebran  1 , Hussein Khachfe  1 , Rudy El Asmar  1 , Ibrahim Nassour  1 , Sowmya Narayanan  1 , Samer AlMasri  1 , Aatur Singhi  2 , Kenneth Lee  1 , Amer Zureikat  1 , Alessandro Paniccia  1
Affiliations

Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma

Asmita Chopra et al. J Surg Oncol. 2024 Dec.

Abstract

Background: Distal pancreatic ductal adenocarcinoma (D-PDAC) often presents at an advanced stage. The efficacy of neoadjuvant therapy (NAT) in improving outcomes for D-PDAC is not well-established. This study evaluates the impact of NAT on the oncological outcomes of patients with D-PDAC.

Methods: A retrospective cohort study of consecutive patients with resectable and borderline-resectable D-PDAC treated at a single center from 2012 to 2020 was performed. Stratification was based on initial treatment-NAT or surgery first (SF). Survival analysis, following intention-to-treat framework, used Kaplan-Meier and Cox regression to assess NAT's impact on progression-free survival (PFS) and overall survival (OS) of D-PDAC.

Results: Among 141 patients (median age 69.8 years, 51.8% females) included in the study, 71 (50.4%) received NAT and 70 (49.6%) were planned for SF. Patients receiving NAT were younger (65.9 vs. 72.6 years) and had higher incidence of borderline-resectable disease (31% vs. 4.3%) (both p < 0.05) than those undergoing SF. Thirteen patients (18.3%) undergoing NAT and five (7.1%) in SF group, failed to undergo resection. Univariate comparison showed no difference in the PFS (SF:13.97 vs. NAT:17.00 months, p = 0.6), and OS (SF:23.73 vs. NAT:32.53 months, p = 0.35). Multivariate Cox regression analysis noted significantly improved PFS (HR = 0.64, 95%CI = 0.42-0.96, p = 0.031) and OS (HR = 0.60, 95%CI = 0.39-0.93, p = 0.021) with NAT.

Conclusion: NAT is associated with improved PFS and OS in patients with -D-PDAC. Further randomized controlled trials are warranted to confirm these findings.

Keywords: chemotherapy; distal; neoadjuvant; pancreatic adenocarcinoma; survival.

PubMed Disclaimer

References

    1. Surveillance Research Program, National Cancer Institute, 2023, https://seer.cancer.gov/statistics-network/explorer/.
    1. F. N. van Erning, T. M. Mackay, L. G. M. van der Geest, et al., “Association of the Location of Pancreatic Ductal Adenocarcinoma (Head, Body, Tail) With Tumor Stage, Treatment, and Survival: A Population‐Based Analysis,” Acta Oncologica 57, no. 12 (December 2018): 1655–1662, https://doi.org/10.1080/0284186X.2018.1518593.
    1. L. K. Winer, V. K. Dhar, K. Wima, et al., “The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma,” Journal of Surgical Research 239 (July 2019): 60–66, https://doi.org/10.1016/j.jss.2019.01.061.
    1. L. M. Youngwirth, D. P. Nussbaum, S. Thomas, et al., “Nationwide Trends and Outcomes Associated With Neoadjuvant Therapy in Pancreatic Cancer: An Analysis of 18243 Patients,” Journal of Surgical Oncology 116, no. 2 (August 2017): 127–132, https://doi.org/10.1002/jso.24630.
    1. Y. Nagakawa, Y. Sahara, Y. Hosokawa, et al., “Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery,” Annals of Surgical Oncology 26, no. 6 (June 2019): 1629–1636, https://doi.org/10.1245/s10434-018-07131-8.

MeSH terms

LinkOut - more resources